HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup AnalysisPaul G. Richardson, Joan Bladé Creixenti, María‐Victoria Mateos et al.|Blood|2020Cited by 11
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup AnalysisMaría‐Victoria Mateos, Paul G. Richardson, Paula Rodríguez‐Otero et al.|Blood|2020Cited by 6
HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional AgentsJoan Bladé Creixenti, Paul G. Richardson, María‐Victoria Mateos et al.|Blood|2020Cited by 5
Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk PopulationPaul G. Richardson, Joan Bladé, María‐Victoria Mateos et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 3
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly PatientsAlessandra Larocca, María‐Victoria Mateos, Paul G. Richardson et al.|Blood|2020Cited by 3